Comparative Oncology Special Interest Group

The link between Human and Animal Cancers

Comparative Oncology
Jessica J Talbot BSc(Vet) research student

Jessica J Talbot

Comparative Oncology is a multidisciplinary approach to exploit animal tumours as models in order to increase our understanding of basic cancer mechanisms as well as their treatment. Naturally occurring cancers of animals share biological, clinical and therapeutic similarities to human cancers making them appropriate models for tumour biology.

Animal cancer models can be used to generate novel knowledge, translate biological concepts regarding cancer to relevant in vivo models, and bring novel therapeutic options to the management of human cancers.

Comparative Oncology Special Interest Group (CO-SIG)
Dr Beata Ujvari Head/Convener of CO-SIG

Dr Beata Ujvari

The Comparative Oncology Special Interest Group (CO-SIG) at the Faculty of Veterinary Sciences, University of Sydney was established in 2012 as a multidisciplinary biomedical, diagnostic pipeline linking clinicians, oncologists, epidemiologists and molecular researchers, pursuing broad-based clinical and interdisciplinary approaches for an increased understanding and treatment of cancer in all species.

The researchers and clinicians at the Faculty of Veterinary Sciences investigate a range of spontaneously occurring animal cancers, which provide excellent opportunities for clinical trials and biological studies and allow early and humane testing of novel therapies.

  • The Comparative Oncology Special Interest Group aims to promote discussion between human and animal cancer researchers for the mutual benefit of both communities.
  • The CO-SIG aspires to develop interdisciplinary cancer research and clinical training programs.
  • The CO-SIG will promote the use of naturally occurring animal cancers as comparative models for human cancer research, diagnostics and treatment.
  • The CO-SIG will create interdisciplinary synergies, and highlight the latest developments in both animal and human cancers to assist the development of cutting-edge cancer research and therapeutics.